{"id":56550,"date":"2026-02-06T22:25:06","date_gmt":"2026-02-06T14:25:06","guid":{"rendered":"https:\/\/flcube.com\/?p=56550"},"modified":"2026-02-06T22:25:07","modified_gmt":"2026-02-06T14:25:07","slug":"fosun-pharmas-fumaining-wins-priority-review-for-nf1-adult-indication-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56550","title":{"rendered":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a><\/strong>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted for review<\/strong> its market application for <strong>Fumaining (luvometinib)<\/strong>, a <strong>MEK1\/2 inhibitor<\/strong>, for adult patients with <strong>type 1 neurofibromatosis (NF1)<\/strong> accompanied by <strong>symptomatic, inoperable plexiform neurofibromas (PN)<\/strong>. The filing has been granted <strong>priority review status<\/strong>, accelerating the regulatory pathway.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Fosun Pharmaceutical (SHA: 600196, HKG: 2196)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Fumaining (luvometinib) \u2013 MEK1\/2 inhibitor<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Market application accepted; priority review granted<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Adult NF1 with symptomatic, inoperable PN<\/td><\/tr><tr><td><strong>Review Timeline<\/strong><\/td><td>Accelerated under priority review pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-approved-amp-pending-indications\">Approved &amp; Pending Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Patient Population<\/th><th>Status<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>Langerhans cell histiocytosis (LCH)<\/strong><\/td><td>Adults<\/td><td>Approved<\/td><td>May\u202f2025<\/td><\/tr><tr><td><strong>Histiocytic neoplasms<\/strong><\/td><td>Adults<\/td><td>Approved<\/td><td>May\u202f2025<\/td><\/tr><tr><td><strong>NF1 with symptomatic, inoperable PN<\/strong><\/td><td>Pediatric\/adolescent (\u22652 years)<\/td><td>Approved<\/td><td>May\u202f2025<\/td><\/tr><tr><td><strong>LCH<\/strong><\/td><td>Pediatric (\u22652 years)<\/td><td>Under review<\/td><td>2025\u20112026<\/td><\/tr><tr><td><strong>NF1 with symptomatic, inoperable PN<\/strong><\/td><td>Adults<\/td><td>Priority review<\/td><td>Filed Feb\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>MEK1\/2 (mitogen\u2011activated protein kinase kinase)<\/strong> \u2013 Key node in RAS\u2011RAF\u2011MEK\u2011ERK signaling pathway<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Inhibition of MEK1\/2 blocks aberrant MAPK signaling driving tumor growth in NF1\u2011associated plexiform neurofibromas and histiocytic disorders<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Oral small\u2011molecule inhibitor<\/li>\n\n\n\n<li><strong>Regulatory Designation:<\/strong> Included in <strong>SPARK Project<\/strong> (Pilot Program to Encourage Development of Pediatric Anti\u2011Tumor Drugs), facilitating pediatric oncology development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NF1 Market Opportunity:<\/strong> Type 1 neurofibromatosis affects approximately <strong>1 in 3,000 individuals globally<\/strong>, with plexiform neurofibromas causing significant morbidity; approved MEK inhibitors (selumetinib, mirdametinib) have established the therapeutic class, creating reimbursement and prescriber familiarity for Fumaining entry.<\/li>\n\n\n\n<li><strong>Pediatric\u2011to\u2011Adult Expansion:<\/strong> Fumaining\u2019s <strong>pediatric NF1 approval (May\u202f2025)<\/strong> now extends to adult population, capturing full age spectrum and maximizing addressable market within single regulatory asset.<\/li>\n\n\n\n<li><strong>Priority Review Advantage:<\/strong> NMPA <strong>priority review status<\/strong> typically compresses review timelines by <strong>30\u201150%<\/strong>, positioning potential approval in <strong>H2 2026<\/strong> and enabling rapid commercial launch.<\/li>\n\n\n\n<li><strong>SPARK Project Validation:<\/strong> Inclusion in China\u2019s pediatric oncology incentive program underscores Fumaining\u2019s <strong>orphan disease strategy<\/strong> and may facilitate future label expansions in rare histiocytic disorders.<\/li>\n\n\n\n<li><strong>Fosun Oncology Portfolio:<\/strong> Fumaining complements Fosun\u2019s existing <strong>biologic and small\u2011molecule oncology assets<\/strong>, strengthening its position in <strong>rare disease and pediatric oncology<\/strong> segments with high pricing power and limited competition.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-outlook\">Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Driver<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Adult NF1 market access<\/strong><\/td><td>Doubles addressable population vs. pediatric\u2011only label<\/td><\/tr><tr><td><strong>Priority review timeline<\/strong><\/td><td>Accelerated revenue recognition potential<\/td><\/tr><tr><td><strong>SPARK Project support<\/strong><\/td><td>Regulatory fast\u2011track for additional pediatric indications<\/td><\/tr><tr><td><strong>MEK inhibitor class growth<\/strong><\/td><td>Expanding reimbursement coverage for targeted NF1 therapies in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Fumaining regulatory review timelines, NF1 market expansion, and Fosun Pharmaceutical\u2019s rare disease commercialization strategy. Actual results may differ due to NMPA review outcomes, competitive dynamics in the MEK inhibitor space, and pricing negotiation results for rare disease indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600196_20260206_SLCZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260206_SLCZ.\"><\/object><a id=\"wp-block-file--media-4f9740f3-970e-4916-b53d-7053e447829d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600196_20260206_SLCZ.pdf\">600196_20260206_SLCZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600196_20260206_SLCZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4f9740f3-970e-4916-b53d-7053e447829d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56553,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,159,893,38,892,33],"class_list":["post-56550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-fosun-pharmaceutical","tag-hkg-2196","tag-market-approval-filings","tag-sha-600196","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56550\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56550\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T14:25:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China\",\"datePublished\":\"2026-02-06T14:25:06+00:00\",\"dateModified\":\"2026-02-06T14:25:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0609.webp\",\"keywords\":[\"Cancer\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Market approval filings\",\"SHA: 600196\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56550#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56550\",\"name\":\"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0609.webp\",\"datePublished\":\"2026-02-06T14:25:06+00:00\",\"dateModified\":\"2026-02-06T14:25:07+00:00\",\"description\":\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\\\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56550\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56550#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56550","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China","og_description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.","og_url":"https:\/\/flcube.com\/?p=56550","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T14:25:06+00:00","article_modified_time":"2026-02-06T14:25:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56550#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56550"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China","datePublished":"2026-02-06T14:25:06+00:00","dateModified":"2026-02-06T14:25:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56550"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56550#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","keywords":["Cancer","Fosun Pharmaceutical","HKG: 2196","Market approval filings","SHA: 600196","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56550#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56550","url":"https:\/\/flcube.com\/?p=56550","name":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56550#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56550#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","datePublished":"2026-02-06T14:25:06+00:00","dateModified":"2026-02-06T14:25:07+00:00","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that the National Medical Products Administration (NMPA) has accepted for review its market application for Fumaining (luvometinib), a MEK1\/2 inhibitor, for adult patients with type 1 neurofibromatosis (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). The filing has been granted priority review status, accelerating the regulatory pathway.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56550#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56550"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56550#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","width":1080,"height":608,"caption":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56550#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma\u2019s Fumaining Wins Priority Review for NF1 Adult Indication in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56550"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56550\/revisions"}],"predecessor-version":[{"id":56554,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56550\/revisions\/56554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}